Tacit Therapeutics, a new startup focused on RNA editing, has successfully secured $19 million in its initial funding round. The company aims to develop treatments targeting various brain diseases.
Founded recently, Tacit Therapeutics is pioneering innovative approaches in the biotech sector. The funding will support the advancement of its research and product development efforts.
Investors are optimistic about the potential impact of Tacit's technology on neurological conditions. The company is set to utilize these funds to further explore its RNA editing capabilities.